on OXURION (EBR:OXUR)
Oxurion completes acquisition of 72% of Axiodis CRO
Oxurion NV, a biopharmaceutical company based in Leuven, announced the completion of its acquisition of a 72% stake in Axiodis CRO. Axiodis CRO, a French company specializing in clinical data management, is renowned for its proprietary eCRF Exagis platform. This transaction marks a crucial step in Oxurion's external growth strategy.
Oxurion will work closely with Axiodis' management team to support its development. The company is also intensifying discussions with other potential targets in France and Europe, with the aim of strengthening an integrated clinical data hub.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news